Lifecycle Approaches for Robust Control Strategies | Digital CMC Summit | Keynote

Taking drug development to a new level of digital precision and predictability

Across the industry, CMC leaders continue to struggle with a range of critical goals – reducing time-to-market, streamlining tech transfers, minimizing batch failures, and more – that can only be achieved through transformative maturation of the drug manufacturing process. Data science experts like Dr. Christoph Herwig are leading the effort to help drug developers achieve that evolution.

He and his fellow researchers are focused on laying the groundwork for the shift from tightly controlled methods and reactively tested outputs to agile, flexible, continuously adaptive processes. The key to that transition: powerful, responsive, multi-dimensional control strategies that synthesize data from across the product lifecycle.

A leading innovator in data science applications for bioprocess designs, Dr. Herwig took 2022 Summit attendees on a deep-dive tour of how new digital modeling methods are shaping the next generation of drug manufacturing processes. In his keynote presentation, he shared in-depth scientific insights on:

• The development and deployment of digital twins, and how they can lay the foundation for continuous bioprocessing.
• How a holistic lifecycle approach to these models can help maximize consistency and quality across development stages and unit operations
• Why drug developers need to set new data management and architecture standards to fully unlock the industry-wide potential of these innovations
• A new model workflow for developing and implementing robust, end-to-end control strategies that can help CMC leaders achieve their performance goals

Sign up today to stream Dr. Herwig’s keynote, and see how the new digital future of CMC is taking shape.